Alphatec (NASDAQ:ATEC) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Alphatec (NASDAQ:ATEC) announced its quarterly earnings results on Tuesday. The medical technology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01), Briefing.com reports. The business had revenue of $138.48 million for the quarter, compared to analysts’ expectations of $134.07 million. During the same quarter last year, the business posted ($0.40) earnings per share. The firm’s quarterly revenue was up 26.9% compared to the same quarter last year.

Alphatec Stock Performance

Shares of Alphatec stock opened at $11.34 on Friday. The firm has a market cap of $1.59 billion, a PE ratio of -7.32 and a beta of 1.48. Alphatec has a 1 year low of $8.66 and a 1 year high of $19.14. The firm’s 50-day simple moving average is $13.21 and its 200-day simple moving average is $13.53. The company has a debt-to-equity ratio of 6.54, a quick ratio of 1.99 and a current ratio of 2.86.

Insider Buying and Selling

In other Alphatec news, CFO John Todd Koning sold 37,500 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $12.82, for a total transaction of $480,750.00. Following the transaction, the chief financial officer now owns 393,356 shares of the company’s stock, valued at approximately $5,042,823.92. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Alphatec news, CFO John Todd Koning sold 37,500 shares of the stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total transaction of $480,750.00. Following the sale, the chief financial officer now directly owns 393,356 shares of the company’s stock, valued at $5,042,823.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Sponsel sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $16.16, for a total transaction of $40,400.00. Following the completion of the transaction, the executive vice president now directly owns 637,418 shares in the company, valued at approximately $10,300,674.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 285,069 shares of company stock worth $3,971,495. Corporate insiders own 29.12% of the company’s stock.

Analyst Ratings Changes

ATEC has been the subject of a number of research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price target on shares of Alphatec in a research report on Wednesday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Monday, March 4th. Wells Fargo & Company began coverage on Alphatec in a research report on Friday, February 9th. They set an “overweight” rating and a $26.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Alphatec in a research report on Wednesday. Finally, Piper Sandler reduced their target price on shares of Alphatec from $19.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat, Alphatec presently has a consensus rating of “Moderate Buy” and an average price target of $22.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.